Insmed Statistics
Total Valuation
Insmed has a market cap or net worth of $37.53 billion. The enterprise value is $36.59 billion.
Important Dates
The next estimated earnings date is Thursday, February 19, 2026, before market open.
| Earnings Date | Feb 19, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Insmed has 213.27 million shares outstanding. The number of shares has increased by 22.43% in one year.
| Current Share Class | 213.27M |
| Shares Outstanding | 213.27M |
| Shares Change (YoY) | +22.43% |
| Shares Change (QoQ) | +11.86% |
| Owned by Insiders (%) | 0.66% |
| Owned by Institutions (%) | 91.29% |
| Float | 191.31M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 74.93 |
| Forward PS | 40.08 |
| PB Ratio | 39.56 |
| P/TBV Ratio | 50.10 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 81.85 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.63, with a Debt / Equity ratio of 0.78.
| Current Ratio | 4.63 |
| Quick Ratio | 4.18 |
| Debt / Equity | 0.78 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -11.81 |
Financial Efficiency
Return on equity (ROE) is -165.69% and return on invested capital (ROIC) is -37.18%.
| Return on Equity (ROE) | -165.69% |
| Return on Assets (ROA) | -28.05% |
| Return on Invested Capital (ROIC) | -37.18% |
| Return on Capital Employed (ROCE) | -50.95% |
| Revenue Per Employee | $351,709 |
| Profits Per Employee | -$931,423 |
| Employee Count | 1,271 |
| Asset Turnover | 0.20 |
| Inventory Turnover | 0.96 |
Taxes
In the past 12 months, Insmed has paid $4.74 million in taxes.
| Income Tax | 4.74M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +167.76% in the last 52 weeks. The beta is 1.09, so Insmed's price volatility has been similar to the market average.
| Beta (5Y) | 1.09 |
| 52-Week Price Change | +167.76% |
| 50-Day Moving Average | 190.03 |
| 200-Day Moving Average | 128.09 |
| Relative Strength Index (RSI) | 43.49 |
| Average Volume (20 Days) | 3,861,957 |
Short Selling Information
The latest short interest is 8.93 million, so 4.19% of the outstanding shares have been sold short.
| Short Interest | 8.93M |
| Short Previous Month | 9.87M |
| Short % of Shares Out | 4.19% |
| Short % of Float | 4.67% |
| Short Ratio (days to cover) | 3.06 |
Income Statement
In the last 12 months, Insmed had revenue of $447.02 million and -$1.18 billion in losses. Loss per share was -$6.22.
| Revenue | 447.02M |
| Gross Profit | 342.15M |
| Operating Income | -990.28M |
| Pretax Income | -1.18B |
| Net Income | -1.18B |
| EBITDA | -978.79M |
| EBIT | -990.28M |
| Loss Per Share | -$6.22 |
Full Income StatementBalance Sheet
The company has $1.68 billion in cash and $740.14 million in debt, with a net cash position of $939.85 million or $4.41 per share.
| Cash & Cash Equivalents | 1.68B |
| Total Debt | 740.14M |
| Net Cash | 939.85M |
| Net Cash Per Share | $4.41 |
| Equity (Book Value) | 945.57M |
| Book Value Per Share | 4.45 |
| Working Capital | 1.51B |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$883.40 million and capital expenditures -$22.74 million, giving a free cash flow of -$906.14 million.
| Operating Cash Flow | -883.40M |
| Capital Expenditures | -22.74M |
| Free Cash Flow | -906.14M |
| FCF Per Share | -$4.25 |
Full Cash Flow StatementMargins
Gross margin is 76.54%, with operating and profit margins of -221.53% and -264.83%.
| Gross Margin | 76.54% |
| Operating Margin | -221.53% |
| Pretax Margin | -263.77% |
| Profit Margin | -264.83% |
| EBITDA Margin | -218.96% |
| EBIT Margin | -221.53% |
| FCF Margin | n/a |
Dividends & Yields
Insmed does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -22.43% |
| Shareholder Yield | -22.43% |
| Earnings Yield | -3.15% |
| FCF Yield | -2.41% |
Dividend DetailsAnalyst Forecast
The average price target for Insmed is $187.30, which is 6.44% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $187.30 |
| Price Target Difference | 6.44% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 22 |
| Revenue Growth Forecast (5Y) | 60.96% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on March 3, 2011. It was a reverse split with a ratio of 1:10.
| Last Split Date | Mar 3, 2011 |
| Split Type | Reverse |
| Split Ratio | 1:10 |
Scores
Insmed has an Altman Z-Score of 3.4 and a Piotroski F-Score of 2.
| Altman Z-Score | 3.4 |
| Piotroski F-Score | 2 |
